Old Drugs, New Cures Act

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 2542 Introduced in House (IH)] <DOC> 119th CONGRESS 1st Session H. R. 2542 To amend titles XVIII and XIX of the Social Security Act to provide that priority research drugs shall not be treated as line extensions of existing drugs for purposes of calculating manufacturer rebates under the Medicare and Medicaid programs, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 1, 2025 Mr. Davis of North Carolina (for himself and Mr. Pfluger) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend titles XVIII and XIX of the Social Security Act to provide that priority research drugs shall not be treated as line extensions of existing drugs for purposes of calculating manufacturer rebates under the Medicare and Medicaid programs, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Old Drugs, New Cures Act''. SEC. 2. PRIORITY RESEARCH DRUGS. (a) In General.--Section 1927(c)(2)(C) of the Social Security Act (42 U.S.C. 1396r-8(c)(2)(C)) is amended by inserting the following new clause before the flush matter at the end: ``(iv) Priority research drug.-- ``(I) Request for designation.--Not later than 90 days following the date of enactment of this clause, the Secretary shall establish and make effective a process for the manufacturer of a covered outpatient drug to request that the Secretary designate the drug as a priority research drug.